BMJ Open Prevalence of multimorbidity with frailty and associations with socioeconomic position in an adult population: findings from the crosssectional HUNT Study in Norway

Kristin Hestmann Vinjerui ,^{1,2} Pauline Boeckxstaens,³ Kirsty A Douglas,⁴ Erik R Sund^{1,5,6}

ABSTRACT

Objectives To explore prevalences and occupational group inequalities of two measures of multimorbidity with frailty.

Design Cross-sectional study.

Setting The Nord-Trøndelag Health Study (HUNT), Norway, a total county population health survey, 2006–2008. **Participants** Participants older than 25 years, with complete questionnaires, measurements and occupation data were included.

Outcomes ≥2 of 51 multimorbid conditions with ≥1 of 4 frailty measures (poor health, mental illness, physical impairment or social impairment) and ≥ 3 of 51 multimorbid conditions with ≥ 2 of 4 frailty measures. Analysis Logistic regression models with age and occupational group were specified for each sex separately. Results Of 41 193 adults, 38 027 (55% female; 25–100 years old) were included. Of them, 39% had \geq 2 multimorbid conditions with ≥1 frailty measure, and 17% had \geq 3 multimorbid conditions with \geq 2 frailty measures. Prevalence differences in percentage points (pp) with 95% confidence intervals of those in high versus low occupational group with ≥ 2 multimorbid conditions and ≥ 1 frailty measure were largest in women age 30 years, 17 (14 to 20) pp and 55 years, 15 (13 to 17) pp and in men age 55 years, 15 (13 to 17) pp and 80 years, 14 (9 to 18) pp. In those with \geq 3 multimorbid conditions and \geq 2 frailty measures, prevalence differences were largest in women age 30 years, 8 (6 to 10) pp and 55 years, 10 (8 to 11) ppand in men age 55 years, 9 (8 to 11) pp and 80 years, 6 (95% CI 1 to 10) pp.

Conclusion Multimorbidity with frailty is common, and social inequalities persist until age 80 years in women and throughout the lifespan in men. To manage complex multimorbidity, strategies for proportionate universalism in medical education, healthcare, public health prevention and promotion seem necessary.

INTRODUCTION

Multimorbidity, the co-occurrence of multiple, chronic conditions, where none is more central,¹ is increasingly prevalent and

Strengths and limitations of this study

- The HUNT Study is a large total county population general health survey with a multitude of variables, suitable to estimate prevalences of multimorbidity and frailty by self-reports and clinical measurements.
- Occupation is used as a marker for socioeconomic position, enabling international comparison.
- Sex-specific occupational group differences in multimorbidity with frailty are reported as both absolute and relative measures of inequality.
- As a secondary analysis, the measures in this study need to be adjusted to fit previously collected data.
- In particular, the original data lacked information of chronicity of conditions, which may lead to overestimation of multimorbidity.

is becoming the norm.^{2–4} Multimorbidity is associated with high healthcare utilisation⁵ and challenges clinicians in a fragmented healthcare system, aided by single disease guidelines.⁶ The treatment burden to patients is often substantial including lowered ability to self-care.⁶ Ways to harmonise guidelines to fit multimorbidity^{7 8} and manage patients with multimorbidity in clinical practice⁶ have been explored, and specific multimorbidity care guidelines are emerging.^{9 10}

Multimorbidity alone may not imply a need for complex, multidisciplinary care.¹ Sociodemographic characteristics, individual health and social experiences, and mental and somatic health characteristics¹¹ increase patient complexity. The British National Institute for Health and Care Excellence (NICE) guideline¹⁰ defines multimorbidity as two or more long-term, single-count health conditions and recommends a multimorbid approach to care in various contexts,

Boeckxstaens P, Douglas KA, *et al.* Prevalence of multimorbidity with frailty and associations with socioeconomic position in an adult population: findings from the cross-sectional HUNT Study in Norway. *BMJ Open* 2020;**10**:e035070. doi:10.1136/ bmjopen-2019-035070

To cite: Vinierui KH.

Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2019-035070).

Received 17 October 2019 Revised 11 March 2020 Accepted 09 April 2020

Check for updates

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Kristin Hestmann Vinjerui; kristin.vinjerui@ntnu.no

Open access




Figure 1 Flowchart for sample selection: inclusion and exclusion criteria and missing data.

including mixed mental and somatic multimorbidity and multimorbidity with frailty.

Frailty increases the vulnerability for adverse outcomes. It has been understood as characterised by loss of biophysical reserves in elderly,¹² operationalised as the frailty phenotype.¹² Another approach is the frailty index,¹³ which calculates a ratio of accumulation of numerous deficits in several domains. An opinion of experts further emphasises the latter multidimensional view and defines frailty as a dynamic state of multicausality, involving loss of function in spheres such as physical, psychological and social domains.¹⁴ This can be regarded as a biopsychosocial frailty model.¹⁵ The NICE guideline proposes identification of frailty through observation of a low gait speed or poor self-rated health or by scoring a frailty scale combining demographic characteristics and multidimensional impairments.¹⁰

Social health inequalities are established; low socioeconomic position is associated with poorer health outcomes in Nordic countries¹⁶ and globally.¹⁷ Multimorbidity and frailty are no exception. Common determinants are socioeconomic deprivation,¹⁸ ¹⁹ female sex^{18 20} and higher age.^{18 20} In descriptive studies, any indicator of socioeconomic position will detect occurring differences.²¹ Socioeconomic gradients in prevalence of multimorbidity and frailty have been explored by education,¹⁸ ¹⁹ ²² ²³ income,²² ²³ occupation³ and deprivation indexes.^{18 19} Occupation is associated with education and income and may have an impact on health outcomes through biopsychosocial work exposures.²¹ Although proportions with multimorbidity and frailty increase with higher age, more multimorbid are young and middle aged than old,^{4 24} and frailty is associated with multimorbidity and mortality from middle age.²⁵ The NICE guideline emphasises assessment of a multimorbid approach to care for adults of all ages but does not take into account social position.

There are numerous operational definitions of both multimorbidity and frailty and prevalence vary by setting, definitions and methods.¹⁸ ^{26–28} The literature suggests that multimorbidity, defined as three or more single health conditions, increases specificity especially in older age groups.²⁶ ²⁹ Common frailty scales require multidimensional loss of function to identify frail individuals²⁰

and share ability to show associations to age, sex and mortality. 20

The overall purpose of this study is to identify how many in a general adult population is likely to need complex, multidisciplinary care as given by one of the contexts suggested by the NICE guideline; multimorbidity with frailty. Two measures will be assessed, one in line with the guideline (two conditions of multimorbidity plus one dimension of frailty) and the other with expected increased specificity (three conditions of multimorbidity plus two dimensions of frailty). The second aim is to examine associations of these measures according to age, sex and socioeconomic position.

MATERIALS AND METHODS Reporting statement

The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) cross-sectional reporting guidelines³⁰ were used for reporting this observational study.

Study design and population

This cross-sectional study use data from the third wave in the Norwegian HUNT Study (the HUNT3 Survey, 2006–2008). Details on data collection and the cohort profile of this total county population health survey were published previously.³¹ In brief, 93 860 residents older than 20 years were invited. Of these. 54% (n=50 807 of 93 860) completed the main questionnaire, meeting the minimum requirement for HUNT3 Survey attendance.³¹ Figure 1 presents the sample selection for this analysis.

Eighty-one per cent (41 193 of 50 807) of eligible participants completed all major parts of the HUNT3 Survey; the main, age-specific and sex-specific questionnaires, interviews and measurements. Incomplete participation excluded 9610 individuals, while four missed complete information on participation. Of the responders, 1569 were younger than 25 years and were excluded on the assumption that the highest level of occupational group may not yet be obtained by those in this age category. One missed information on age. A total of 1571 individuals missed information on occupation, while 25 people had 'unspecified occupation' and was excluded. Of 41 193 (92%) participants, 38 027 were included in the final sample.

Overall, lower socioeconomic position was associated with lower participation rate in the HUNT3 Survey.³² In this study, the distribution of occupational groups was 24% (high), 27% (middle) and 49% (low) in the sample and 17% (high), 20% (middle), 52% (low) and 11% (missing) among non-eligible. One hundred per cent of the missing were due to missing classifiable occupational data. Women constituted 55%, 51% and 81% of the sample, non-eligible and missing, respectively. The mean (SD) age was 55 (14) years in the sample, 44 (18) years among non-eligible and 66 (18) years among those missing data.

Box 1 Conditions grouped by ICD-10 chapter

ICD-10 chapter

Conditions II Neoplasms Cancer III Blood/blood-forming organs/immune mechanism Sarcoidosis IV Endocrine/nutritional/metabolic Obesity Hypercholesterolemia Diabetes Hypothyroidism Hyperthyroidism V Mental/behavioural Alcohol problem Depression Anxietv Insomnia Nervous system Epilepsy Migraine Chronic headache, other VII Eve/adnexa Cataract Macula degeneration Glaucoma **VIII Ear/mastoid** Hearing impairment **IX Circulatory system** Hypertension Angina pectoris Myocardial infarction Heart failure Other heart disease* Stroke or brain haemorrhage* X Respiratory system Chronic bronchitis, emphysema or COPD* Asthma **XI Digestive system** Dental health status Gastro-oesophageal reflux disease Irritable bowel syndrome XII Skin/subcutaneous tissue Hand eczema **Psoriasis** XIII Musculoskeletal/connective tissue **Rheumatoid arthritis** Osteoarthritis Ankylosing spondylitis Fibromyalgia Osteoporosis Local musculoskeletal pain/stiffness in: Neck or upper back or lower back or shoulder or elbow or Hand or hip or knee or foot/ankle **XIV** Genitourinary system Kidney disease Urine incontinence Prostate symptoms Menopausal hot flashes

Continued

XVIII Symptoms/signs/abnormal clinical/laboratory findings Nocturia. Chronic widespread pain.

*Exception to single entity. COPD, Chronic Obstructive Pulmonary Disease.

Demographic and socioeconomic characteristics

Sex and age at participation in the HUNT3 Survey was constructed by the HUNT Databank. Occupational group was used as indicator of socioeconomic position.²¹ In the HUNT3 Survey interview, all participants were asked, "What is/was the title of your main occupation?" Freetext answers were manually categorised corresponding to Standard Classifications of Occupations by Statistics Norway,³³ which is based on the International Standard Classification of Occupations-88.34 Occupational socioeconomic position was operationalised using occupation only, corresponding to a simplified version of the European Socio-economic Classification scheme.³⁵ The scheme aims to differentiate occupational groups on employment relationships and is not hierarchical per se. Still, the higher occupational groups are likely to have higher and more secure income.³⁵ Collapsed to a threeclass version, the high level represents large employers. higher grade and lower grade professionals, administrative and managerial occupations, and higher grade technician and supervisory occupations. The middle group consists of small employers, self-employed individuals, and lower-grade supervisory and technician occupations. The low level contains lower-grade service positions, sales and clerical occupations, and lower-grade technical and routine occupations. Details are provided in online supplementary appendix A.

Outcomes

Multimorbidity

The construction of 51 single, chronic conditions from the HUNT3 Survey data is described in online supplementary appendix B. Box 1 lists the 51 conditions by 14 International Classification of Diseases 10th Revision (ICD-10) chapters, a disease classification system in major organised by organ systems. In this study, a simple, nonweighted summary score was generated and two multimorbidity variables created, with cut-off values of at least 2 of 51 and 3 of 51 conditions.

Frailty

Original data did not match any exact frailty scale. A qualitative judgement of available data was undertaken and general, mental, physical and social dimensions^{10 14 20} of frailty were operationalised from six original variables:

1. General health status, defined as those reporting the answers 'poor' or 'not so good' (vs 'good' and 'very good') to the single question, "How is your health at the moment?"

- 2. Mental health status, included those reporting symptoms of anxiety and/or depression, on the Hospital Anxiety and Depression Scale. The HUNT Databank calculated a total score for subscales of anxiety and depression, if all items for anxiety and depression, respectively, were answered. In this study, cut-off was set at 8/21 points for both conditions³⁶ and a combined variable was created.
- 3. Physical impairment was identified by combining those reporting 'yes' (vs 'no') in response to the question, "Do you suffer from any long-term (at least 1year) illness or injury of a physical or psychological nature that impairs your functioning in your daily life?" and reporting either motor ability, vision or hearing impairment to a moderate or severe degree.
- 4. Social impairment was derived from answers to the single question, "To what extent has your physical health or emotional problems limited you in your usual socializing with family or friends during the last 4 weeks?" Included were those reporting 'much' and 'not able to socialise' (vs 'not at all,' 'very little,' or 'somewhat').

A summary score was generated and two frailty variables created, with cut-off values of at least one of four and two of four frailty measures with impairment.

Multimorbidity with frailty

The two final outcome variables were created by combining self-reported multimorbidity and frailty as at least 2 of 51 chronic health conditions plus impairment in 1 of 4 dimensions of frailty and 3 of 51 chronic health conditions plus impairments in 2 of 4 dimensions of frailty.

Statistical analysis

We used cross-tables to identify sociodemographic characteristics by occupational group (table 1) and by multimorbidity with frailty, stratified by sex (table 2).

Associations between occupational group and the two measures of multimorbidity with frailty were analysed using logistic regression, adjusted for age and sex. All models were stratified by sex and included occupational group, continuous age, age squared and an interaction term between occupational group and age. Likelihood ratio tests were used to compare models.

Given the high prevalence of multimorbidity with frailty and the knowledge that odds ratios will deviate from relative risks,³⁷ we used postestimation commands to obtain prevalence differences and prevalence ratios³⁸ between the occupational groups with high occupational group as the reference category. The prevalence difference is the difference in mean predicted probability, and prevalence ratio is the ratio between the mean predicted probabilities while holding other covariates constant.³⁸ Prevalence difference and prevalence ratio between occupational groups were calculated at age 25–100 years in 5-year intervals (online supplementary appendix C). Calculations (with 95% confidence intervals) are presented at the ages 30, 55 and 80 years to reflect young adults, middle aged and elderly (table 3).

We performed complete case analysis and used Stata V.15.1 (StataCorp., College Station, Texas, USA) to analyse the data.

Patient and public involvement

During the preparation of the HUNT3 Survey, there was a wide citizen and stakeholder participation. This study is a secondary analysis of data collected in 2006–2008. Multimorbidity is a universal topic, not represented by any particular patient group, thus no patient or public representatives were involved in designing the study.

RESULTS

A total of 38027 individuals, older than 25 years, who had completed all major parts of the HUNT3 Survey and had data on occupation, comprised the final sample for this study (figure 1). Further sociodemographic characteristics are presented in table 1.

Most participants, 49% (n=18814 of 38027), are categorised as low occupational group, which is comprised of

Table 1 Sex and age distribution by occupational group												
	Occupation	Occupational group										
	High	High		Middle			Total					
	Frequency	(%)	Frequency	(%)	Frequency	(%)	Frequency	(%)				
Total	8970	(100)	10243	(100)	18814	(100)	38027	(100)				
Sex												
Female	4505	(50)	5386	(53)	10922	(58)	20813	(55)				
Male	4465	(50)	4857	(47)	7892	(42)	17214	(45)				
Age, years												
25–44	2837	(32)	2600	(25)	4487	(24)	9924	(26)				
45–64	4468	(50)	4787	(47)	8951	(48)	18206	(48)				
65–74	1118	(12)	1846	(18)	3297	(18)	6261	(16)				
75–100	547	(6)	1010	(10)	2079	(11)	3636	(10)				

 Table 2
 Frequency distribution of two definitions of multimorbidity with frailty across occupational groups and age categories, stratified by sex

Two conditions of multimorbidityand one dimension of							Men						
							Two conditions of multimorbidity and one dimension of frailty*						
No, freq.	(%)	Yes, freq.	(%)	Total, freq.	(%)	No, freq.	(%)	Yes, freq.	(%)	Total, freq.	(%)		
12304	(59)	8482	(41)	20813	(100)	10826	(63)	6378	(37)	17214	(100)		
al group													
3222	(72)	1 282	(28)	4 505	(100)	3220	(72)	1242	(28)	4465	(100)		
3370	(63)	2009	(37)	5386	(100)	2995	(62)	1860	(38)	4857	(100)		
5712	(52)	5191	(48)	10922	(100)	4611	(58)	3276	(42)	7892	(100)		
4298	(72)	1 680	(28)	5 981	(100)	3 075	(78)	867	(22)	3 943	(100)		
5712	(58)	4122	(42)	9 840	(100)	5 398	(65)	2 967	(35)	8 366	(100)		
1615	(51)	1 548	(49)	3 168	(100)	1 681	(54)	1 409	(46)	3 093	(100)		
679	(37)	1 132	(62)	1 824	(100)	672	(37)	1 135	(63)	1 812	(100)		
52	(14)	58	(14)	54	(14)	54	(14)	61	(14)	56	(14)		
	Two cond frailty* No, freq. 12304 al group 3222 3370 5712 4298 5712 1615 679	Two conditions of frailty* No, freq. (%) 12 304 (59) al group 3222 (72) 3370 (63) 5712 (52) 4298 (72) 5712 (58) 1615 (51) 679 (37)	Space Space <th< td=""><td>Space Science Space Sc</td><td>Two conditions of multimorbidityand one dimerization on the frailty* No, freq. (%) Yes, freq. (%) Total, freq. 12 304 (59) 8 482 (41) 20 813 al group 3222 (72) 1 282 (28) 4 505 3 370 (63) 2 009 (37) 5 386 5 712 (52) 5 191 (48) 10 922 4 298 (72) 1 680 (28) 5 981 5 712 (58) 4 122 (42) 9 840 1615 (51) 1 548 (49) 3 168 679 (37) 1 132 (62) 1 824</td><td>Two conditions of multimorbidityand one dimension of frailty* No, freq. (%) Yes, freq. (%) Total, freq. (%) 12 304 (59) 8 482 (41) 20 813 (100) al group 3222 (72) 1 282 (28) 4 505 (100) 3370 (63) 2 009 (37) 5 386 (100) 5712 (52) 5191 (48) 10 922 (100) 4298 (72) 1 680 (28) 5 981 (100) 5712 (58) 4 122 (42) 9 840 (100) 1615 (51) 1 548 (49) 3 168 (100) 679 (37) 1 132 (62) 1 824 (100)</td><td>Two conditions of multimorbidityand one dimension of frailty*Two conditions frailty*No, freq.(%)Yes, freq.(%)freq.(%)No, freq.12 304(59)8 482(41)20 813(100)10 826al group3222(72)1 282(28)4 505(100)3 2203370(63)2 009(37)5 386(100)2 9955712(52)5191(48)10 922(100)4 6114298(72)1 680(28)5 981(100)5 3981 615(51)1 548(49)3 168(100)1 681679(37)1 132(62)1 824(100)672</td><td>Two conditions of multimorbidityand one dimension of frailty*Two conditions of frailty*No, freq.(%)Yes, freq.(%)Freq.(%)No, freq.(%)12 304(59)8 482(41)20 813(100)10 826(63)al group3222(72)1 282(28)4 505(100)3 220(72)3 370(63)2 009(37)5 386(100)2 995(62)5712(52)5 191(48)10 922(100)4 611(58)4298(72)1 680(28)5 981(100)3 075(78)5712(58)4 122(42)9 840(100)5 398(65)1 615(51)1 548(49)3 168(100)1 681(54)679(37)1 132(62)1 824(100)672(37)</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>Two conditions of multimorbidityand one dimension of frailty*Two conditions of multimorbidity and frailty*No, freq.(%)Yes, freq.(%)Total, freq.No, freq.(%)Yes, freq.(%)12 304(59)8 482(41)20 813(100)10 826(63)6 378(37)al group3222(72)1 282(28)4 505(100)3 220(72)1 242(28)3370(63)2 009(37)5 386(100)2 995(62)1 860(38)5712(52)5 191(48)10 922(100)4 611(58)3 276(42)4298(72)1 680(28)5 981(100)3 075(78)867(22)5712(58)4 122(42)9 840(100)5 398(65)2 967(35)1615(51)1 548(49)3 168(100)1 681(54)1 409(46)679(37)1 132(62)1 824(100)672(37)1 135(63)</td><td>Two conditions of multimorbidityand one dimension of frailty*Two conditions of multimorbidity and one dimension of frailty*No, freq.(%)Yes, freq.Total, (%)No, freq.(%)Yes, freq.Total, freq.12 304(59)8 482(41)20 813(100)10 826(63)6 378(37)17214al group3222(72)1 282(28)4 505(100)3220(72)1 242(28)4 4653370(63)2 009(37)5 386(100)2 995(62)1 860(38)4 8575712(52)5 191(48)10 922(100)4 611(58)3 276(42)7 8924298(72)1 680(28)5 981(100)3 075(78)867(22)3 9435712(58)4 122(42)9 840(100)5 398(65)2 967(35)8 3661615(51)1 548(49)3 168(100)1 681(54)1 409(46)3 093679(37)1 132(62)1 824(100)672(37)1 135(63)1 812</td></th<>	Space Science Space Sc	Two conditions of multimorbidityand one dimerization on the frailty* No, freq. (%) Yes, freq. (%) Total, freq. 12 304 (59) 8 482 (41) 20 813 al group 3222 (72) 1 282 (28) 4 505 3 370 (63) 2 009 (37) 5 386 5 712 (52) 5 191 (48) 10 922 4 298 (72) 1 680 (28) 5 981 5 712 (58) 4 122 (42) 9 840 1615 (51) 1 548 (49) 3 168 679 (37) 1 132 (62) 1 824	Two conditions of multimorbidityand one dimension of frailty* No, freq. (%) Yes, freq. (%) Total, freq. (%) 12 304 (59) 8 482 (41) 20 813 (100) al group 3222 (72) 1 282 (28) 4 505 (100) 3370 (63) 2 009 (37) 5 386 (100) 5712 (52) 5191 (48) 10 922 (100) 4298 (72) 1 680 (28) 5 981 (100) 5712 (58) 4 122 (42) 9 840 (100) 1615 (51) 1 548 (49) 3 168 (100) 679 (37) 1 132 (62) 1 824 (100)	Two conditions of multimorbidityand one dimension of frailty*Two conditions frailty*No, freq.(%)Yes, freq.(%)freq.(%)No, freq.12 304(59)8 482(41)20 813(100)10 826al group 3222 (72)1 282(28)4 505(100)3 2203370(63)2 009(37)5 386(100)2 9955712(52)5191(48)10 922(100)4 6114298(72)1 680(28)5 981(100)5 3981 615(51)1 548(49)3 168(100)1 681679(37)1 132(62)1 824(100)672	Two conditions of multimorbidityand one dimension of frailty*Two conditions of frailty*No, freq.(%)Yes, freq.(%)Freq.(%)No, freq.(%)12 304(59)8 482(41)20 813(100)10 826(63)al group 3222 (72)1 282(28)4 505(100)3 220(72)3 370(63)2 009(37)5 386(100)2 995(62)5712(52)5 191(48)10 922(100)4 611(58)4298(72)1 680(28)5 981(100)3 075(78)5712(58)4 122(42)9 840(100)5 398(65)1 615(51)1 548(49)3 168(100)1 681(54)679(37)1 132(62)1 824(100)672(37)	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Two conditions of multimorbidityand one dimension of frailty*Two conditions of multimorbidity and frailty*No, freq.(%)Yes, freq.(%)Total, freq.No, freq.(%)Yes, freq.(%)12 304(59)8 482(41)20 813(100)10 826(63)6 378(37)al group 3222 (72)1 282(28)4 505(100)3 220(72)1 242(28)3370(63)2 009(37)5 386(100)2 995(62)1 860(38)5712(52)5 191(48)10 922(100)4 611(58)3 276(42)4298(72)1 680(28)5 981(100)3 075(78)867(22)5712(58)4 122(42)9 840(100)5 398(65)2 967(35)1615(51)1 548(49)3 168(100)1 681(54)1 409(46)679(37)1 132(62)1 824(100)672(37)1 135(63)	Two conditions of multimorbidityand one dimension of frailty*Two conditions of multimorbidity and one dimension of frailty*No, freq.(%)Yes, freq.Total, (%)No, freq.(%)Yes, freq.Total, freq.12 304(59)8 482(41)20 813(100)10 826(63)6 378(37)17214al group 3222 (72)1 282(28)4 505(100)3220(72)1 242(28)4 4653370(63)2 009(37)5 386(100)2 995(62)1 860(38)4 8575712(52)5 191(48)10 922(100)4 611(58)3 276(42)7 8924298(72)1 680(28)5 981(100)3 075(78)867(22)3 9435712(58)4 122(42)9 840(100)5 398(65)2 967(35)8 3661615(51)1 548(49)3 168(100)1 681(54)1 409(46)3 093679(37)1 132(62)1 824(100)672(37)1 135(63)1 812		

Three conditions of multimorbidity and two dimensions of frailty* of frailty*

	No, freq.	(%)	Yes, freq.	(%)	Total, freq.	(%)	No, freq.	(%)	Yes, freq.	(%)	Total, freq.	(%)
Total	16983	(82)	3803	(18)	20813	(100)	14367	(83)	2837	(16)	17214	(100)
Occupation	al group											
High	4029	(89)	475	(11)	4 505	(100)	3977	(89)	485	(11)	4465	(100)
Middle	4491	(83)	888	(16)	5386	(100)	3995	(82)	860	(18)	4857	(100)
Low	8463	(77)	2440	(22)	10922	(100)	6395	(81)	1492	(19)	7892	(100)
Age, years												
25–44	5378	(90)	600	(10)	5981	(100)	3651	(93)	291	(7)	3943	(100)
45–64	7920	(80)	1914	(19)	9840	(100)	7024	(84)	1341	(16)	8366	(100)
65–74	2449	(77)	714	(23)	3168	(100)	2472	(80)	618	(20)	3093	(100)
75–100	1236	(68)	575	(32)	1824	(100)	1220	(67)	587	(32)	1812	(100)
Mean (SD)	53	(14)	60	(14)	54	(14)	55	(14)	63	(13)	56	(14)

*In total, 27 women and 10 men miss data on both measures of multimorbidity with frailty. freq., frequency.

58% (n=10922 of 18 814) women, while women constitute 55% (n=20813 of 38027) of the total sample.

In total, 77% reported more than two and 62% more than three conditions of multimorbidity. Frailty with one impairment was identified in 41% and with two impairments in 18%. Table 2 shows the distribution of the combined measures across occupational groups and stratified by sex.

Overall, 39% met the criteria of having at least two conditions of multimorbidity with one dimension of frailty (41% (n=8482 of 20813) of women, 37% (n=6378 of 17214) of men) and 17% met the criteria of three-condition multimorbidity with two dimensions of frailty (18% (n=3803 of 20813) of women, 16% (n=2837 of 17 214) of men).

Proportions of multimorbidity with frailty increased with lower occupational rank and increasing age, in both sexes, regardless of definition. Most individuals with any definition of multimorbidity with frailty were younger than 64 years.

Table 3 shows prevalence differences and prevalence ratios with 95% CI for each definition of multimorbidity with frailty between occupational groups for women and men at the ages 30, 55 and 80 years.

Prevalence differences in percentage points (pp) for two-condition multimorbidity with one dimension of frailty between high and low occupational groups were largest in women at 30 years, 17 (14 to 20) pp and 55 years, 15 (13 to 17) pp, and for men at 55 years, 15 (13 to 17) pp and 80 years, 14 (9 to 18) pp. The prevalence ratio Table 3 Prevalence ratios (PR) and prevalence differences (PD) with 95% CI between occupational groups and multimorbidity with frailty, stratified by sex

		Women				Men						
Age,	Occupational	Two conditions of multimorbidity and one dimension of frailty										
years	group	PR	(95% CI)	(95% CI) PD		PR	(95% CI)	PD	(95% CI)			
30	High	1.00	1.00 (Ref.) 0.00		(Ref.)	1.00	(Ref.)	0.00	(Ref.)			
	Middle	1.36	(1.11 to 1.65)	0.06	(0.02 to 0.09)	0.93	(0.70 to 1.23)	-0.01	(-0.06 to 0.03)			
	Low	2.09	(1.76 to 2.47)	0.17	(0.14 to 0.20)	1.32	(1.04 to 1.67)	0.05	(0.01 to 0.09)			
55	High	1.00	(Ref.)	0.00	(Ref.)	1.00	(Ref.)	0.00	(Ref.)			
	Middle	1.22	(1.13 to 1.31)	0.07	(0.04 to 0.09)	1.34	(1.23 to 1.45)	0.08	(0.06 to 0.11)			
	Low	1.48	(1.38 to 1.58)	0.15	(0.13 to 0.17)	1.60	(1.48 to 1.72)	0.15	(0.13 to 0.17)			
80	High	1.00	(Ref.)	0.00	(Ref.)	1.00	(Ref.)	0.00	(Ref.)			
	Middle	0.96	(0.86 to 1.08)	-0.02	(-0.09 to 0.05)	1.23	(1.12 to 1.35)	0.12	(0.06 to 0.17)			
	Low	1.05	(0.95 to 1.16)	0.03	(-0.03 to 0.09)	1.27	(1.15 to 1.39)	0.14	(0.09 to 0.18)			
Age,	Occupational	Three conditions of multimorbidity and two dimensions of frailty										
years	group	PR	(95% CI)	PD	(95% CI)	PR	(95% CI)	PD	(95% CI)			
30	High	1.00	(Ref.)	0.00	(Ref.)	1.00	(Ref.)	0.00	(Ref.)			
	Middle	2.31	(1.56 to 3.40)	0.04	(0.02 to 0.06)	1.29	(0.77 to 2.17)	0.01	(-0.01 to 0.03)			
	Low	3.59	(2.53 to 5.08)	0.08	(0.06 to 0.10)	1.60	(1.02 to 2.51)	0.02	(0.00 to 0.04)			
55	High	1.00		0.00		1.00		0.00				
	Middle	1.31	(1.14 to 1.50)	0.04	(0.02 to 0.06)	1.62	(1.40 to 1.87)	0.06	(0.04 to 0.07)			
	Low	1.78	(1.59 to 2.00)	0.10	(0.08 to 0.11)	2.05	(1.80 to 2.33)	0.09	(0.08 to 0.11)			
80	High	1.00	(Ref.)	0.00	(Ref.)	1.00	(Ref.)	0.00	(Ref.)			
	Middle	1.17	(0.94 to 1.47)	0.05	(-0.02 to 0.11)	1.26	(1.06 to 1.50)	0.07	(0.02 to 0.11)			
	Low	1.16	(0.94 to 1.42)	0.04	(-0.01 to 0.10)	1.22	(1.04 to 1.44)	0.06	(0.01 to 0.10)			

for the low occupational group compared with the high occupational group, for two-condition multimorbidity with one dimension of frailty, was greatest in women at 30 years, 2.09 (1.76 to 2.47) and in men at 55 years, 1.60 (1.48 to 1.72). The prevalence ratio decreased in both sexes in high age and was at 80 years 1.05 (0.95 to 1.16) for women and 1.27 (1.15 to 1.39) for men.

Correspondingly, prevalence differences between high and low occupational groups for three-condition multimorbidity with two dimensions of frailty were largest in women at 30 years, 8 (6 to 10) pp and 55 years, 10 (8 to 11) pp and in men at 55 years, 9 (8 to 11) pp and 80 years, 6 (1 to 10) pp. Prevalence ratio, comparing the low occupational group with the highest occupational group for three-conditions multimorbidity with two conditions of frailty, was greatest in women at 30 years, 3.59 (1.43 to 5.08) and in men at 55 years, 2.05 (1.80 to 2.33). The prevalence ratio decreased in both sexes in high age and was at 80 years 1.16 (0.94 to 1.42) for women and 1.22 (1.04 to 1.44) for men.

DISCUSSION Main results

Main results

In this adult population health study, multimorbidity with frailty was common as 39% met the criteria of two-condition multimorbidity plus one dimension of frailty and 17% met the criteria of three-condition multimorbidity plus two dimensions of frailty. Proportions increased with lower occupational group, higher age and female sex from 25 to 74 years, but was common across age groups in both sexes. Occupational inequalities were consistent in both sexes until high age, diminishing in women, while still present in men at age 80 years.

Comparison with existing literature

Investigating two measures of multimorbidity with frailty in one sample offers a unique direct comparison of occurrences and socioeconomic gradients. Lower overall prevalence for the stricter measure three-condition multimorbidity with two dimensions of frailty is expected. Defining multimorbidity by three or more conditions differentiates into older age.^{26 29} The joint measure multimorbidity and frailty show the same tendency, as 62% of 75–100 year olds met the criteria of at least two-condition multimorbidity with one dimension of frailty, while 32% reported three-condition multimorbidity with two dimensions of frailty. In line with individual studies on multimorbidity⁴²⁴ and frailty,²⁵ most individuals with co-present multimorbidity and frailty are younger than 64 years.

A recent commentary¹ emphasised exploring multimorbidity guidelines and frailty as part of multimorbidity's complexity, and overlap of multimorbidity and frailty has newly been reviewed.²⁸ A pooled prevalence of 16% (95% CI 12% to 21%) was reported for two conditions multimorbidity with the frailty phenotype among elderly,²⁸ while 39% in our study reported at least two conditions of multimorbidity with one dimension of frailty. The prevalence differences are likely explained by differences in methods. The articles included in the review studied age 60 years and older. Still, the prevalence of multimorbidity is low. All but one defined multimorbidity from lists of less than 12 conditions and prevalences are probably underestimated.^{26 29} Frailty too was only operationalised with the biophysical model, while more people are expected to be detected using a multidimensional measure.

We have not identified studies on prevalence and social determinants of multimorbidity with frailty. Low social position,^{18 19} older age^{18 20} and female sex^{18 20} are known common determinants of multimorbidity and frailty. We therefore argue that the direction of the sociodemographic determinants in this study is as expected. The magnitudes of these gradients, however, have not been comparable with other studies.

Mechanisms to explain findings

The aggregation of ill health, multimorbidity and frailty included in lower socioeconomic positions is explained by numerous theories. Overall, unequal distribution of power, income and resources result in fundamental different conditions of daily life vielding inequalities in health.¹⁷ With regard to occupation, several mechanisms can explain associations to health outcomes. The higher occupational group is expected to have higher, more stable income,^{35,39} more beneficial social networks³⁹ and more autonomy and control^{35 39} at work. Adverse working conditions such as exposure to toxic work environments²¹ or demanding physical requirements³⁹ tend to cluster in lower occupational groups.¹⁷ Persisting health inequalities in assumed egalitarian Nordic countries is partly understood as mortality selection, where, given the well-developed healthcare and welfare systems, frail individuals survive, but likely end up in a low social position.¹⁶ Further, smoking, overall morbidity and mortality decrease at a higher rate among higher than lower social groups.¹⁶ In this study, the demographic age distribution explain the high number of 45 to 64 years old with co-present multimorbidity and frailty. Additionally, incidence of new conditions is associated with count of conditions at baseline,⁴ as well as age,⁴ thus individuals in lower occupational groups may aggregate conditions faster. The bidirectional association of health and occupation may explain higher occupational group prevalence ratios in younger individuals,²¹ while lower ratios by increasing age are expected, since multimorbidity with frailty is more common⁴⁰ with advancing age. Finally, survival bias justifies diminishing occupational differences at age 80 years.

Strengths and limitations

Materials and methods meet the standards of studies on multimorbidity, frailty and social health inequalities, strengthening this study. In multimorbidity studies, population-based health surveys are the most frequent study design,⁴¹ and prevalence estimates from self-reports are justified when studying large samples.²⁶ Deriving the condition count multimorbidity measures from a complete list of single-entity conditions is shown to yield proper prevalence estimates.²⁹ A multidimensional frailty measure agrees with a holistic, unrestricted on age, conceptual definition of frailty¹⁴ and with common frailty scales, which share ability to show associations to age, sex and mortality.²⁰ In descriptive studies, any measure of socioeconomic position will reveal health inequalities, if such exists.²¹ Occupation is an established marker for socioeconomic position,²¹ in which this study had individual data classified to facilitate international comparison. Finally, socioeconomic differences are explored as both absolute and relative measures¹⁶ and presented by sex.¹⁸

There are always limitations in secondary analysis of data collected a priori and not for the purpose of the current study. Measures of multimorbidity and frailty are also manifold, and operationalisations were adjusted to fit the available data. This challenges the external validity, and comparability between studies, however, is sought reduced through transparency of morbidities included and construction of variables. A majority of included multimorbidity conditions do not contain information regarding duration. Thus, reported prevalence of multimorbidity may be overestimated and not represent true chronicity. It is recognised that frailty scales may differ in accuracy of detecting frailty in younger age groups^{10 20}; however, frailty symptoms are of great clinical value regardless of age.^{10 42} The accuracy of the frailty variables were not explored and frailty was measured solely as self-report, an approach that may underestimate overall prevalence⁴³ and overestimate proportion among women compared with men.⁴³

Lastly, in the HUNT3 Survey, participants were asked for their 'main' occupation, which is not necessarily the current or longest lasting occupation, more commonly studied.³⁹ Younger than middle aged may to some extent be misclassified in the lower occupational group, which will underestimate social differences in health among younger subjects. Occupational data may obscure current social context³⁹ and underestimate socioeconomic inequalities. Thus, the study would have benefitted from exploring socioeconomic position with several indicators,⁴⁴ such as individual education and income or a household measure.

Attendance in the HUNT3 Survey varied by age, sex and social position³²; still, the HUNT Study is considered representative for Norway as a whole⁴⁵ and the cohort follows trends in health development in western high-income countries.^{46–48} Depression hindered participation,³² which may yield underestimation of both multimorbidity and frailty. An overall bias towards healthy elders is probable, since eligibility depended on attendance at a screening station.

Implications for clinical practice and policy makers

This study aimed to quantify the total prevalence of adults in the general population who might need complex, multidisciplinary care assessed as the joint measure multimorbidity with frailty. In a clinical context, the definition of at least three-condition multimorbidity with two dimensions of frailty to detect individuals for whom to initiate a multimorbid approach to care seems more feasible. Despite acknowledgement of the association of multimorbidity and frailty with age, sex and socioeconomic position, guidelines and interventions have yet to take this into account in assessment and management for multimorbidity.⁴⁹ Based on literature and reproduction of social gradients in our study, we suggest that clinicians consider evaluation of multimorbidity and frailty in younger age groups with social context in mind. Further research on implementation of the multimorbid approach to care model and mortality is needed before recommending changing inclusion criteria in a guideline. Since multimorbidity is becoming the norm, the organisation of healthcare should reform to fit person-centred, coordinated, multidisciplinary care.^{6 10 50} To prevent cases of multimorbidity and frailty and minimise social discrepancies, both universal and targeted life cycle approaches seem necessary.⁵¹

Frailty is independently associated with mortality, adjusted for multimorbidity,²⁵ and is reversible.⁵² Thus, detection of frailty is relevant for both public health and clinical purposes.

Future research

Some forms of biases are possible for both multimorbidity, frailty and social position, and a careful interpretation of findings is warranted. However, multimorbidity with frailty is common in this general population and with occupational inequalities throughout adulthood, even with stricter definitions. This adds knowledge to the public health literature about the sociodemographic distribution of multimorbidity with frailty in younger age groups, as well as very old individuals. On this background, we recommend exploring the sociodemographic distribution of alternative measures on multimorbidity, including patterns, aiming to detect individuals suspected in high need of complex, multidisciplinary healthcare. Furthermore, such measurements can be compared as prognostic factors for healthcare utilisation and mortality.

CONCLUSION

Multimorbidity with frailty is common from young adulthood onward, with consistent socioeconomic inequalities until 80 years old. Prevention will require a proportionate universal approach on social determinants of health throughout the entire life span. The crucial need for person-centred multimorbid approach to care that acknowledges social context, demands reforms in healthcare organisational structure, medical education and treatment. Further research on competing measures of high-need multimorbidity and the association of these factors with healthcare utilisation and mortality should be explored by socioeconomic position, age and sex.

Author affiliations

¹Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, HUNT Research Centre, Norwegian University of Science and Technology, NTNU, Trondheim, Norway

²Psychiatric Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

³Department of Public Health and Primary Care, Ghent University, Ghent, Belgium ⁴Australian National University Medical School, Australian National University, Canberra, Australian Capital Territory, Australia

⁵Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway
⁶Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

Twitter Kristin Hestmann Vinjerui @KHVinjerui

Acknowledgements L Getz, J Sigurdsson and C Harrison for thorough discussions on measures of multimorbidity. E Solheim for guidance in the use of the European Socio-economic Classification scheme. MS Newman for writing assistance. The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU)), Nord-Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health.

Contributors KHV, ERS and KAD conceptualised the study and all authors contributed to its design. KHV has analysed the data under the supervision of ERS and all authors have contributed to interpreting the data. KHV wrote the original draft, which has been revised critically by ERS, KAD and PB. All authors have read and approved the final version of the manuscript to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This study was funded by the Faculty of Medicine and Health Science at the Norwegian University of Science and Technology (NTNU) through the PhD programme in Behaviour and Health (KHV). NTNU has partly funded the HUNT3 Survey and have funded open access for this article. The Liaison Committee for Education, Research and Innovation in Central Norway (17/38297) supported a research stay for KHV at the Australian National University, Canberra. The funding sources have had no role in conceptualization this study, its design and methods, analysis and interpretation of data, writing of the article or the decision to submit the article for publication.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The Regional Committee for Medical and Health Research Ethics in Norway approved the current study (Project No. 2014/2265).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. To protect participants' privacy, HUNT Research Centre aims to limit storage of data outside HUNT databank and cannot deposit data in open repositories. HUNT databank has precise information on all data exported to different projects and are able to reproduce these on request. There are no restrictions regarding data export given approval of applications to HUNT Research Centre. For more information, see http:// www.ntnu.edu/hunt/data.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

6

ORCID iD

Kristin Hestmann Vinjerui http://orcid.org/0000-0003-1828-6943

REFERENCES

- Nicholson K, Makovski TT, Griffith LE, et al. Multimorbidity and comorbidity revisited: Refining the concepts for international health research. J Clin Epidemiol 2019;105:142–6.
- 2 van Oostrom SH, Gijsen R, Stirbu I, et al. Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys. *PLoS One* 2016;11:e0160264.
- 3 Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract* 2008;14:28–32.
- 4 van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998;51:367–75.
- 5 Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. *Fam Pract* 2011;28:516–23.
- 6 Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. BMJ 2015;350:h176.
- 7 Guthrie B, Payne K, Alderson P, et al. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012;345:e6341.
- 8 Muth C, Kirchner H, van den Åkker M, *et al.* Current guidelines poorly address multimorbidity: pilot of the interaction matrix method. *J Clin Epidemiol* 2014;67:1242–50.
- 9 Palmer K, Marengoni A, Forjaz MJ, et al. Multimorbidity care model: recommendations from the consensus meeting of the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). *Health Policy* 2018;122:4–11.
- 10 National Institute for Health and Care Excellence. *Multimorbidity: clinical assessment and management*. London: National Institute for Health and Care Excellence (UK), 2016.
- 11 Schaink AK, Kuluski K, Lyons RF, et al. A scoping review and thematic classification of patient complexity: offering a unifying framework. J Comorb 2012;2:1–9.
- 12 Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–57.
- 13 Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *ScientificWorldJournal* 2001;1:323–36.
- 14 Gobbens RJJ, Luijkx KG, Wijnen-Sponselee MT, *et al.* In search of an integral conceptual definition of frailty: opinions of experts. *J Am Med Dir Assoc* 2010;11:338–43.
- 15 Solfrizzi V, Scafato E, Lozupone M, *et al.* Biopsychosocial frailty and the risk of incident dementia: the Italian longitudinal study on aging. *Alzheimers Dement* 2019;15:1019–28.
- 16 Huijts T, Eikemo TA, Causality ETA. Causality, social selectivity or artefacts? why socioeconomic inequalities in health are not smallest in the Nordic countries. *Eur J Public Health* 2009;19:452–3.
- 17 Commission on Social Determinants of Health. *Closing the gap in a generation: health equity through action on the social determinants of health: final report of the Commission on social determinants of health.* Geneva, 2008.
- 18 Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102149.
- 19 Franse CB, van Grieken A, Qin L, et al. Socioeconomic inequalities in frailty and frailty components among community-dwelling older citizens. PLoS One 2017;12:e0187946.
- 20 Theou O, Brothers TD, Peña FG, *et al.* Identifying common characteristics of frailty across seven scales. *J Am Geriatr Soc* 2014;62:901–6.
- 21 Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. *Br Med Bull* 2007;81-82:21–37.
- 22 Agborsangaya CB, Lau D, Lahtinen M, et al. Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey. *BMC Public Health* 2012;12:201.
- 23 Szanton SL, Seplaki CL, Thorpe RJ, et al. Socioeconomic status is associated with frailty: the women's health and aging studies. J Epidemiol Community Health 2010;64:63–7.
- 24 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43.
- 25 Hanlon P, Nicholl BI, Jani BD, et al. Frailty and pre-frailty in middleaged and older adults and its association with multimorbidity and

mortality: a prospective analysis of 493 737 UK Biobank participants. *Lancet Public Health* 2018;3:e323–32.

- 26 Fortin M, Stewart M, Poitras M-E, et al. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012;10:142–51.
- 27 O'Caoimh R, Galluzzo L, Rodríguez-Laso Ángel, et al. Prevalence of frailty at population level in European advantage joint action member states: a systematic review and meta-analysis. Ann Ist Super Sanita 2018;54:226–38.
- 28 Vetrano DL, Palmer K, Marengoni A, et al. Frailty and multimorbidity: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 2019;74:659–66.
- 29 Harrison C, Britt H, Miller G, et al. Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice. BMJ Open 2014;4:e004694.
- 30 von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495–9.
- 31 Krokstad S, Langhammer A, Hveem K, *et al*. Cohort profile: the HUNT study, Norway. *Int J Epidemiol* 2013;42:968–77.
- 32 Langhammer A, Krokstad S, Romundstad P, et al. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Med Res Methodol* 2012;12:143.
- 33 Norway S. Standard classification of occupations. Statistics Norway: Oslo/Kongsvinger, 1998.
- 34 International Labour Organization (ILO). The International Standard Classification of Occupations, ISCO-88 [Webpage], 1988. Available: https://www.ilo.org/public/english/bureau/stat/isco/isco88/index.htm
- 35 Rose D, Harrison E. The European socio-economic classification: a new social class schema for comparative European research. *European Societies* 2007;9:459–90.
- 36 Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 2002;52:69–77.
- 37 Sedgwick P. Relative risks versus odds ratios. BMJ 2014;348:g140 7–g07.
- 38 Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. *Stata J* 2013;13:492–509.
- 39 Galobardes B, Shaw M, Lawlor DA, et al. Indicators of socioeconomic position (Part 1). J Epidemiol Community Health 2006;60:7–12.
- 40 Scanlan JP, Editorial G. Guest editorial. CHANCE 2006;19:47-51.
- 41 Willadsen TG, Bebe A, Køster-Rasmussen R, et al. The role of diseases, risk factors and symptoms in the definition of multimorbidity - a systematic review. Scand J Prim Health Care 2016;34:112–21.
- 42 Schuurmans H, Steverink N, Lindenberg S, et al. Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci 2004;59:M962–5.
- 43 Theou O, O'Connell MDL, King-Kallimanis BL, et al. Measuring frailty using self-report and test-based health measures. Age Ageing 2015;44:471–7.
- 44 Braveman PA, Cubbin C, Egerter S, et al. Socioeconomic status in health research: one size does not fit all. JAMA 2005;294:2879–88.
- 45 Holmen J, Midthjell K, Ø K, et al. The Nord-Trøndelag health study 1995–97 (Hunt 2): objectives, contents, methods and participation. Norsk epidemiologi 2003;13:19–32.
- 46 Ncd risk factor collaboration (NCD-RisC). rising rural body-mass index is the main driver of the global obesity epidemic in adults. *Nature* 2019;569:260–4.
- 47 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19-1 million participants. *Lancet* 2017;389:37–55.
- 48 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128-9 million children, adolescents, and adults. *Lancet* 2017;390:2627–42.
- 49 Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ 2012;345:e5205.
- 50 World Health Organization. Multimorbidity: Technical Series on Safer Primary Care. In: *Organization WH*. Geneva: World Health Organization, 2016: 4–5.
- 51 Marmot M, Goldblatt P, Allen J, *et al. Fair Society*. Healthy Lives: The Marmot Review, 2010.
- 52 Gill TM, Gahbauer EA, Allore HG, et al. Transitions between frailty states among community-living older persons. Arch Intern Med 2006;166:418–23.